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Systematic literature review assessing tobacco
smoke exposure as a risk factor for serious
respiratory syncytial virus disease among infants
and young children
Joseph R DiFranza1*, Anthony Masaquel2, Amy M Barrett3, Ann D Colosia3 and Parthiv J Mahadevia2
Abstract
Background: The role of environmental tobacco smoke (ETS) exposure as a risk factor for serious respiratory
syncytial virus (RSV) disease among infants and young children has not been clearly established. This systematic
review was conducted to explore the association between ETS exposure and serious RSV disease in children
younger than 5 years, including infants and young children with elevated risk for serious RSV disease.
Methods: A systematic review of English-language studies using the PubMed and EMBASE databases (1990–2009)
was performed to retrieve studies that evaluated ETS as a potential risk factor for serious RSV illness. Studies
assessing risk factors associated with hospitalization, emergency department visit, or physician visit due to RSV
(based on laboratory confirmation of RSV or clinical diagnosis of RSV) in children under the age of 5 years were
included.
Results: The literature search identified 30 relevant articles, categorized by laboratory confirmation of RSV infection
(n = 14), clinical diagnosis of RSV disease (n = 8), and assessment of RSV disease severity (n = 8). Across these three
categories of studies, at least 1 type of ETS exposure was associated with statistically significant increases in risk in
multivariate or bivariate analysis, as follows: 12 of 14 studies on risk of hospitalization or ED visit for laboratory-
confirmed RSV infection; 6 of 8 studies of RSV disease based on clinical diagnosis; and 5 of the 8 studies assessing
severity of RSV as shown by hospitalization rates or degree of hypoxia. Also, 7 of the 30 studies focused on
populations of premature infants, and the majority (5 studies) found a significant association between ETS exposure
and RSV risk in the multivariate or bivariate analyses.
Conclusion: We found ample evidence that ETS exposure places infants and young children at increased risk of
hospitalization for RSV-attributable lower respiratory tract infection and increases the severity of illness among
hospitalized children. Additional evidence is needed regarding the association of ETS exposure and outpatient RSV
lower respiratory tract illness. Challenges and potential pitfalls of assessing ETS exposure in children are discussed.
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Background
Almost all children contract respiratory syncytial virus
(RSV) by 2 years of age [1]. RSV causes upper airway
infections, bronchiolitis, wheezy bronchitis, and pneu-
monia. Although most infections produce mild disease,
RSV is a major cause of hospitalization in infants [2]
and can be fatal [3]. Premature infants, infants with
bronchopulmonary dysplasia (BPD) (chronic lung dis-
ease of prematurity), and infants with congenital heart
disease are at risk for serious infections [4,5]. Risk fac-
tors for RSV infection include exclusive bottle feeding
[6,7], having older brothers or sisters in the household
[6,8,9], male gender [10], low birth weight [10,11], pre-
maturity [6], household crowding [12], and young
chronologic age [9]. Although exposure to environmen-
tal tobacco smoke (ETS) is a risk factor for asthma,
wheezing, decreased pulmonary function, otitis media,
cough, and lower respiratory tract infections (LRTIs) in
general [13], its role in the development of serious RSV
disease among infants and young children is less clear
and has been a topic of interest among the healthcare
community [14].
In this systematic review, we evaluated the evidence of
an association between ETS exposure and serious RSV
disease among children younger than 5 years. To obtain
the broadest understanding of whether ETS exposure
affects the risk of serious RSV disease, we placed no lim-
its on the type of proxy measures of ETS exposure.
Understanding the evidence basis for ETS exposure and
RSV could highlight the need to direct healthcare
resources or intervention programs toward this poten-
tially modifiable risk factor.
Methods
Patient population
In this systematic literature review, we included studies
of infants and children up to 5 years of age, including
studies of children at high risk for serious RSV disease.
We defined the high-risk population as patients with
prematurity, BPD, or congenital heart disease. All other
patient populations were defined as general populations,
which consisted predominantly of children not defined
as high risk.
Search strategy
Following PRISMA guidelines, we conducted a system-
atic review of the association of ETS exposure with ser-
ious RSV disease by searching broadly for studies
assessing various risk factors, including ETS exposure,
for RSV, bronchiolitis, or LRTI caused by RSV or bron-
chiolitis.[15] We searched the PubMed (including MED-
LINE) and EMBASE databases for English-language
studies published and indexed between 1990 and April
2009. No additional relevant unpublished studies were
obtained. Studies that identified ETS exposure as a risk
factor might be more likely to mention ETS in the title
or abstract than studies that evaluated ETS exposure in
a set of other risk factors, but did not find it to be sig-
nificantly associated with increased risk. To minimize
article selection bias across studies, we searched for arti-
cles that assessed any risk factors for RSV as well as
bronchiolitis, because 50% to 80% of winter bronchiolitis
is due to RSV in infants and young children [1]. For
PubMed, the National Library of Medicine Medical Sub-
ject Headings (MeSH terms) used in the search included
tobacco smoke pollution/adverse effects, respiratory syn-
cytial virus infections, bronchiolitis viral, and respiratory
tract infections in combination with the MeSH subhead-
ings epidemiology, etiology, and complications. The
MeSH heading respiratory tract infections was combined
with the keywords syncytial or RSV OR bronchiolitis or
the MESH term tobacco smoke pollution/adverse effects.
Studies that included risk assessment were identified
using the following MeSH headings: analysis of variance
(which includes multivariate analysis), probability (which
includes proportional hazards model, odds ratio, risk,
risk assessment, and risk factors); and case–control stud-
ies or cohort studies, which were combined with the
terms relative risk OR hazard ratio OR odds ratio. The
search identified studies with the following combination
of these terms: (1) any disease-related term plus any risk
assessment term; or (2) any disease-related term plus the
smoke exposure term. We did not search for unpub-
lished studies or reports.
Study selection
Each relevant article was read by several authors and the
bibliographies of included articles were reviewed for
additional studies. We excluded studies that did not as-
sess disease risk or did not include ETS exposure as a
risk factor. Figure 1 presents a summary of exclusions
and rationales for exclusion during successive rounds
of review.
Data extraction
Study details were extracted into tables, and table content
was verified by a second author and by a reviewer not
involved in the data extraction. The authors discussed
each article to reach consensus regarding the study details.
For each study the following data were extracted: refer-
ence, publication year, country origin, study design, study
population size and description, assessment method for
ETS exposure (e.g., maternal smoking through birth cer-
tificate data), method of ascertainment of RSV status (if
any, such as through laboratory confirmation or clinical
diagnosis), disease outcome evaluated (e.g., hospitalization
for RSV), and results and significance of multivariate,
bivariate, and other statistical analyses. Outcomes related
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to the presence of RSV antibodies without evidence of
hospitalization, ED visit, or physician visit related to RSV
were not extracted. The principal summary measures were
adjusted odds ratios (aORs), adjusted rate ratios (aRRs), or
adjusted hazard ratios (aHRs) for multivariate analyses
and odds ratios (ORs) for bivariate analyses. Several stud-
ies that did not perform multivariate analyses performed
between-group comparisons and presented P values.
Assessment of risk of bias
Among the studies meeting the inclusion criteria, we
evaluated the risk of bias at the outcome and study level
using the Cochrane risk of bias tool [16]. The Cochrane
risk of bias tool was developed primarily for use in inter-
ventional studies; we used the tool to examine factors
specific to sources of bias frequently found in observa-
tional studies. The studies were examined for risk of bias
that would potentially influence the association of ETS
exposure with serious RSV disease. The studies were
judged regarding evidence of misclassification bias of
RSV disease, selective reporting bias, confounding bias,
exposure ascertainment bias, or participant selection
bias. Disease misclassification bias was assessed based
on the likelihood of the study population having an
LRTI that was not due to RSV. We expect that disease
misclassification would underestimate the association
Figure 1 PRISMA Flow Diagram: Summary of Exclusions and Rationales for Exclusion During Phases of Systematic Literature Review.
PRISMA= Preferred Reporting Items for Systematic Reviews and Meta-Analyses; LRTI = lower respiratory tract infection; MeSH=medical subject
headings; RSV = respiratory syncytial virus.
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between ETS exposure and serious RSV disease. Select-
ive reporting bias was evaluated based on whether out-
comes related to risk factors were clearly reported.
Confounding bias was assessed based on whether the
study controlled for the effects of other variables
through multivariate analysis. We expect that unadjusted
results may overestimate the association between ETS
exposure and serious RSV disease. Exposure ascertain-
ment bias was assessed based on whether the ETS ex-
posure variables were described clearly and determined
by the study authors to be adequate measures of ETS ex-
posure in the study population. Finally, participant selec-
tion bias was pointed out in case–control studies in
which the control group consisted of ill patients with
non-RSV respiratory disease, and therefore, the effect of
ETS exposure on serious RSV disease could be biased
toward the null.
Results
The search of PubMed and EMBASE databases yielded
699 unique results, and the abstracts were reviewed for
relevance (Figure 1). Of these, 676 were excluded
through successive rounds of review, the majority be-
cause the studies did not focus on a disease of interest
(RSV, bronchiolitis, or LRTI attributable to RSV or bron-
chiolitis), were not conducted in a population of interest
(children younger than 5 years without serious nonre-
spiratory disease, such as cancer or organ transplant), or
did not assess ETS exposure.
Full review of 57 articles resulted in the exclusion of
34 articles, leaving 23 articles identified by the electronic
search. The addition of 7 articles identified from refer-
ences cited (4 were published before 1990) produced a
total of 30 relevant articles.
Overview of studies
The results are organized by study characteristics and
include a bias assessment summary for each study. (The
full bias assessment is presented in Additional file 1:
Table S1) Table 1 presents 14 studies that established a
diagnosis of RSV disease by confirmatory laboratory
testing. These studies compared children with RSV
infections with children without respiratory illness and
assessed whether ETS exposure increased the risk for
developing a serious RSV infection. Table 2 presents 8
studies that did not confirm suspected cases of RSV dis-
ease with laboratory testing, but relied on the clinical
diagnosis of RSV or bronchiolitis, often from medical
charts or insurance data. These studies also compared
children with RSV or bronchiolitis infections with chil-
dren without respiratory illness. Table 3 presents 8 stud-
ies that examined the impact of ETS exposure on the
severity of RSV disease as measured by hospitalization
or degree of hypoxia. These studies started with a
sample of children infected with RSV and assessed
whether ETS exposure increased the severity of the RSV
infection. Within each group of studies, we considered
studies of premature infants separately because this
population is at higher risk for serious RSV disease than
the general population of children [17,18]. We also
present the results by study design (e.g., cohort, case–
control) in each table.
The methods used to assess ETS exposure status var-
ied widely and included mother’s prenatal smoking sta-
tus, mother’s postnatal smoking status, father’s smoking
status, smoking in the home, number of smokers in the
household, number of cigarettes smoked in the home,
more than five cigarettes smoked per day in the home,
days of smoke exposure, history of exposure to smoking,
smoking by daycare provider, and cotinine levels.
Some of the studies summarized included more than
one source of ETS exposure, but no study detailed miss-
ing ETS exposure status data. In the studies reporting
multiple ETS exposure, we have presented all results
based on the different sources (e.g., maternal smoking
during pregnancy and smokers in the household) be-
cause it is difficult to determine in each setting which of
several proxies for total ETS exposure results in the least
misclassification error. Few of the multivariate studies
provided a rationale for their selection of control vari-
ables. We therefore included positive bivariate results in
our tables when bivariate and multivariate analyses pro-
duced disparate conclusions.
ETS exposure and laboratory-confirmed RSV disease
The studies in Table 1 seek to answer the question, does
ETS exposure increase the risk that an uninfected child
will develop serious RSV? In 14 studies, the diagnosis of
RSV infection was confirmed by laboratory testing
(Table 1). Of these, 12 studies showed a significant ad-
verse impact of ETS exposure on serious RSV in bivari-
ate or multivariate analysis as measured by at least one
exposure variable. These studies examined the association
of ETS exposure and other factors on the risk of ED
visit [23] or hospital admission [5,6,9,10,12,19-21,24-26]
for laboratory-confirmed RSV LRTI. Two studies exam-
ining laboratory-confirmed RSV did not find a statisti-
cally significant association between ETS exposure
and serious RSV: a cohort study of outpatients in the
United States assessing the risk of a child presenting to
the pediatrician’s office with an RSV infection [22], and
an Australian case–control study assessing the risk of
RSV hospitalization [11].
Four of these 14 studies contained at least one signifi-
cant association, but found mixed results with different
ETS exposure variables [6,19,20,23]. One prospective co-
hort study in premature infants found that maternal
smoking and parental smoking in the home had
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Table 1 Studies Reporting Risk of Developing Serious RSV (Laboratory-Confirmed RSV; N= 14)
Study, Year, Country Design and Population ETS Exposure Outcome Results Bias Assessment/Comment
Prospective cohort studies in premature infants
Broughton 2005 United
Kingdom [19]
Prospective study of
126 premature infants
(GA <32 wks; 40%
developed BPD)
Maternal smoking
during pregnancy
RSV LRTI
(41% hospitalized)
aOR, 4.85 (95% CI, 1.61–14.58);
P= 0.005
No significant bias concerns
affecting the relationship of ETS
and outcome
Parental smoking
in home
RSV LRTI NS aOR, 0.81 (95% CI, 0.19–3.37);
P= 0.771
Maternal smoking
during pregnancy
Hospital admission
(all cause; 56% of
admissions were RSV LRTI)
NS aOR, 1.19 (95% CI, 0.20–7.07);
P= 0.849
Parental smoking
in home
Hospital admission aOR, 3.39 (95% CI, 1.08–10.63);
P= 0.003
Maternal smoking
during pregnancy
Length of hospital stay NS, P= 0.150 (OR not reported)
Parental smoking
in home
Length of hospital stay P< 0.001 (OR not reported)
Carbonell-Estrany 2001
Spain [9]
Prospective,
longitudinal study of
999 premature infants
(GA ≤32 wks)
Days of smoke
exposure
RSV hospitalization aOR, 1.63 (1.05–2.56); P= 0.031 No significant bias concerns
affecting the relationship of ETS
and outcome
Figueras-Aloy 2008
Spain [20]
2-cohort study of
premature infants
(GA 32–35 wks); 202 cases
hospitalized for RSV and
5239 controls not hospitalized
for respiratory illness
Maternal smoking
during pregnancy
RSV hospitalization aOR, 1.61 (95% CI, 1.16–2.25);
P= 0.004
Authors note relatively high loss to
follow-up of 12% of children
fulfilling inclusion criteria. Both
ETS exposure variables were
significant in bivariate analysis at
P< 0.01, but when included in
multivariate model, only prenatal
smoking was significant, possibly
due to misclassification of ETS
exposure
≤2 smokers
in home
RSV hospitalization NS in multivariate model
Significant in bivariate analysis,
OR 1.59 (95% CI, 1.12–2.26);
P= 0.01
Law 2004 Canada [10] Prospective cohort study
of 1832 premature infants
(GA 33–35 wks)
≥2 smokers
in household
RSV hospitalization aOR, 1.87 (95% CI, 1.07–3.26);
P= 0.027
No significant bias concerns
affecting the relationship of ETS
and outcome
Case–control study in premature infants
Figueras-Aloy 2004
Spain [21]
Case–control study of
premature infants
(GA 33–35 wks); 186 cases
hospitalized for RSV; 371
controls born at same
time as cases
Maternal smoking
during pregnancy
RSV hospitalization NS in multivariate model No significant bias concerns
affecting the relationship of ETS
and outcome
Significant in bivariate analysis
OR, 1.62 (95% CI, 1.08–2.42);
P= 0.027
Maternal smoking
at home
RSV hospitalization NS in bivariate model
OR, 1.49 (95% CI, 1.01–2.18);
P= 0.055
≥2 smokers at home RSV hospitalization NS in bivariate model
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Table 1 Studies Reporting Risk of Developing Serious RSV (Laboratory-Confirmed RSV; N= 14) (Continued)
OR, 1.41 (95% CI, 0.92–2.14);
P= 0.146
Prospective cohort studies in the general population
Holberg 1991 US [22] Prospective birth cohort
study of 1179 healthy
infants followed for 1 year
Maternal smoking RSV diagnosed in an
office visit
NS in multivariate model No significant bias concerns
affecting the relationship of ETS
and outcome
Rate ratio, 1.0 (95% CI, 0.3–3.5)
von Linstow 2008
Denmark [6]
Prospective birth cohort
study of 217 children
followed for 1 year
Smoking in household RSV hospitalization aOR, 5.06 (95% CI, 1.36–18.76);
P< 0.02
No significant bias concerns
affecting the relationship of ETS
and outcome; to reduce problems
with colinearity, only 1–2
variables from each group of
covariates (e.g., social variables,
smoking parameters) were
included in the multivariate model.
Maternal smoking
during pregnancy
RSV hospitalization NS in multivariate model
(OR not reported)
Significant in univariate model
OR, 4.19 (95% CI, 1.21–14.53);
P= 0.024
Case–control studies in the general population
Bulkow 2002
US [12]
Case–control study of
Alaska native children
aged <3 years with 204
cases and 338 controls
Smoker in household RSV hospitalization NS in multivariate model Unclear risk of ETS exposure
misclassification because of high
prevalence of smoking and
frequency of indoor visiting
among households during winter
RSV season; low risk of other types
Significant in bivariate analysis,
OR, 1.61; P≤ 0.018
Gurkan 2000
Turkey [23]
Case–control study of
28 cases and 30 controls
aged 2–18 months
▪Nonsmoking parents
▪Only smoker mother
▪Only smoker father
▪Both parents smokers
RSV bronchiolitis admitted
to the ED Serum cotinine
assessed during ED visit and
1 month later
Significant differences in
cases vs. controls (P< 0.05)
for all ETS exposure variables;
however, only father smoker
was more prevalent in the control
than case group
No multivariate analysis
performed (confounding bias)
Significant differences in
cases vs. controls (P< 0.05)
in cotinine levels for both
parents smokers vs. both
parents nonsmokers and for
only mother smoker vs. both
parents nonsmokers in the
control group
Hall 1984
US [24]
Case–control study
of 29 cases and 58 controls
hospitalized with non
respiratory acute illness
Smoking in household RSV hospitalization Significant difference in
smoking in household in
cases (76%) vs. controls
(40%) (P< 0.05)
No multivariate analysis
performed (confounding bias)
Hayes 1989
American Samoa [25]
Case–control study of
children aged <1 year
(20 cases and 15 well controls)
Smoker in
household
RSV hospitalization
(53% laboratory-confirmed)
Significant difference in
smoker in household in cases
(92%) vs. well controls
(53%) (P= 0.04)
No multivariate analysis
performed (confounding bias)53%
of hospitalizations were
laboratory-confirmed RSV
Nielsen 2003
Denmark [5]
Case–control study of
1252 cases in children
Maternal smoking
during pregnancy
RSV hospitalization aOR, 1.56 (95% CI, 1.32–1.98)
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Table 1 Studies Reporting Risk of Developing Serious RSV (Laboratory-Confirmed RSV; N= 14) (Continued)
aged <2 years and 5 controls
for each case
from the Medical Birth
Register
No significant bias concerns
affecting the relationship of ETS
and outcome
Reeve 2006
Australia [11]
Case–control study with
271 cases and 542 controls
(median age 6 mo)
Maternal smoking RSV hospitalization NS in main multivariate
modelBivariate OR not
reported CART analysis
performed to define groups
that are most homogeneous
with regard to the outcome of
RSV hospitalization. CART
analysis found that smoking
was a risk factor in children
with birthweight >2500 g and
single mothers (41.0% hospitalized
vs. 26.9% for single nonsmoking
mothers)Smoking was not
significant for any other group
Analysis was weakened by
reliance on a questionnaire that did
not seek to quantify ETS exposure
and by the absence of laboratory
confirmation of ETS exposure.63
participants were excluded due to
data unavailability (37 of these
were missing the mother’s
smoking status and 47 had proven
RSV), although the missing data
were not statistically significant
Stensballe 2006
Denmark [26]
Case–control study
of 2564 cases and
12 816 controls from
birth to 18 months
Any maternal smoking
during pregnancy and
lactation
RSV hospitalization aOR, 1.35 (95% CI, 1.20–1.52); P< 0.001 No significant bias concerns
affecting the relationship of ETS
and outcome
aOR = adjusted (multivariate) odds ratio; BPD=bronchopulmonary dysplasia (now chronic lung disease); CART = Classification and regression tree; CI = confidence interval; ED = emergency department;
ETS = environmental tobacco smoke; OR = odds ratio; GA= gestational age; LRTI = lower respiratory tract infection; NS = not significant; RSV = respiratory syncytial virus.
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Table 2 Studies reporting risk of developing serious rsv (clinical diagnosis of rsv illness; N= 8)
Study, Year, Country Design and Population Smoke Exposure Outcome Results Bias Assessment
Cohort study in premature infants
Gavin 2007
US [27]
Retrospective cohort study
of 2098 premature infants
(GA 32–35 weeks) in the
Texas Medicaid program
Maternal smoking
status during pregnancy
from the birth certificate
Insurance claims for
bronchiolitis or RSV
hospitalization in
the first year of life
NS, aOR, 0.78
(95% CI, 0.38–1.61)
Clinical diagnosis of RSV
leading to misclassification
could underestimate ETS
exposure risk
Cohort studies in the general population
Boyce 2000
US [4]
Retrospective cohort study
of children aged <3 years
in the Tennessee Medicaid
program from 1989–1993,
with 248 652 child-years of
follow-up
Maternal smoking
status during pregnancy
from the birth certificate
Insurance claims for
bronchiolitis or RSV
hospitalization in
the first year of life
aRR, 1.3
(95% CI, 1.2–1.4)
Clinical diagnosis of RSV
leading to misclassification
could underestimate ETS
exposure risk
Carroll 2007
US [28]
Retrospective cohort study
of 101 245 term infants
enrolled in the Tennessee
Medicaid program
Maternal smoking
status during pregnancy
from the birth certificate
Insurance claims for
bronchiolitis or RSV
pneumonia in
the first year of life
▪Hospitalization aOR, 1.28
(95% CI, 1.20–1.36)
Clinical diagnosis of RSV
leading to misclassification
could underestimate ETS
exposure risk
▪ED visit aOR, 1.22
(95% CI, 1.13–1.31)
▪Clinic visit aOR, 1.06
(95% CI, 1.01–1.12)
▪Bronchiolitis diagnosis aHR,
1.14 (95% CI, 1.10–1.18)
Koehoorn 2008
Canada [29]
Retrospective cohort study
of 93 058 infants aged
2–12 months
Maternal smoking
status during pregnancy
from perinatal database
Diagnostic codes for
bronchiolitis for
outpatient visits or
hospitalizations
▪Inpatient onlyaHR, 1.47
(95% CI, 1.27–1.69)
Clinical diagnosis of
bronchiolitis leading to
misclassification could
underestimate ETS
exposure risk
▪Outpatient or inpatient NS in
multivariate model, aHR, 1.03
(95% CI, 0.97–1.09)
Maternal smoking during
pregnancy was significant in
bivariate analysis for both
case definitions, but when
included in the multivariate
models, it was significantly
associated only with the
inpatient (more severe) case
definition
▪Significant in bivariate analysis,
OR 1.14 (95% CI, 1.08–1.21);
no P value reported
Marbury 1996
US [30]
Prospective cohort study
of 1424 children with private
insurance followed to
age 2 years
Maternal smoking
status
Diagnosis of
bronchiolitis from
electronic medical
records
NS, aRR, 1.3 (95% CI, 0.8–2.2);
no P value reported
Clinical diagnosis of
bronchiolitis leading to
misclassification could
underestimate ETS exposure
risk The authors noted that
smokers were less likely to
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Table 2 Studies reporting risk of developing serious rsv (clinical diagnosis of rsv illness; N= 8) (Continued)
participate in the study (the
Indoor Air and Children’s
Health Study) and that
smokers who participate
may differ from those who
do not. They also noted the
possibility of underreporting
of smoking
Reese et al., 1992
Australia [18]
Retrospective cohort study
of 491 patients up to
age 17 years admitted
to an Australian children’s
hospital June-Dec. 1987
for whom urinary cotinine
levels were available.
Urinary cotinine level,
analyzed without knowledge
of exposure status
or diagnosis
Hospitalization with
diagnosis of
bronchiolitis vs. a
non-respiratory
diagnosis (limited to
patients aged 5–15
mos in the nonrespiratory
illness group)
Elevated cotinine levels found in
bronchiolitis vs. nonrespiratory
illness group (P< 0.02)
Subanalysis of the bronchiolitis
group by RSV status found no
significant difference between
RSV-positive (n = 16) and
RSV-negative (n = 23) patients;
both subgroups had elevated
cotinine vs. the nonrespiratory
illness group
Risk of confounding not
clear; regression analysis
appears to have been
performed but was
insufficiently reported
(no aORs reported)
Among those with
cotinine levels, 41 patients
(aged 5–15 mos.) were
diagnosed with bronchiolitis
Case–control studies in the general population
Holman 2003
US [3]
Case–control study of
224 infants aged <1 year
who died from bronchiolitis,
and 2336 controls
Maternal smoking
status during pregnancy
Bronchiolitis death from
death certificate data
aOR, 1.6(95% CI, 1.0–2.6) Clinical diagnosis of
bronchiolitis from death
certificate leading to
misclassification could
underestimate ETS
exposure risk
McConnochie 1986
US [31]
Case–control study of
53 cases of bronchiolitis and
106 controls in children
aged <2 years presenting
to a physician’s officeBivariate
analysis included 3 ETS
exposure variables, but only
“passive smoking” was
included in the multivariate
analysis
Any passive smoking Bronchiolitis from diagnostic
registry and record review
aOR, 3.87 if no family history of
asthma (no CI or P value
reported)aOR, 4.03 if family history
of asthma (no CI or P value
reported)
Clinical diagnosis of
bronchiolitis leading to
misclassification could
underestimate ETS exposure
risk Interviews related to
smoking status were
conducted approximately
7.8 years after the
bronchiolitis episodes;
current and former smokers
at the time of the interview
were assumed to be smoking
at the time of the
bronchiolitis episode
Smoking in household Bronchiolitis Bivariate OR, 3.21
(95% CI, 1.42–7.25)
Mother smokes Bronchiolitis Bivariate OR, 2.33
(95% CI, 1.19–4.57)
Father smokes Bronchiolitis NS in bivariate model, OR 1.71
(95% CI, 0.87–3.33)
aHR = adjusted hazard ratio; aOR= adjusted (multivariate) odds ratio; aRR = adjusted rate ratio; CI = confidence interval; ED = emergency department; ETS = environmental tobacco smoke; GA=gestational age;
LRTI = lower respiratory tract infection; NS = not significant; RSV = respiratory syncytial virus; OR=odds ratio.
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Table 3 Studies examining disease severity (N=8)
Study, Year, Country Design and Population Smoke Exposure Outcome Results Bias Assessment
Risk of hospitalization among premature children with RSV illness
Groothuis et al., 1988
US [32]
Prospective cohort study
of 30 premature infants
aged <2 years with BPD
receiving home oxygen therapy;
participants followed for 5 mos
(Dec-Apr)
Smokers in home Risk of hospitalization
(11 of 16 with RSV hospitalized)
vs. outpatient treatment
NS; bivariate analysis reported
and P value not given
No multivariate analysis
performed (confounding
bias)
Risk of hospitalization among children in the general population with RSV illness
Al-Shehri 2005
Saudi Arabia [33]
Case–control study;
51 children aged ≤5 years
hospitalized for bronchiolitis
(cases) and 115 children
with bronchiolitis but not
hospitalized (controls);
40% of cases were RSV
History of exposure
to smoking
Risk of hospitalization vs.
outpatient treatment for
bronchiolitis
aOR, 2.51 (95% CI, 2.11–3.73);
P=0.05
Risk of participant
selection bias because both
cases and controls had
bronchiolitis
Hall 2009 US [2] 919 children aged <5
years with laboratory-confirmed
RSV infections
Smoking in
household
Risk of hospitalization vs.
outpatient treatment
NS in multivariate analysis
(no aOR, CI, or P value)NS
in bivariate analysis (P= 0.43)
No significant bias
concerns affecting the
relationship of ETS and
outcome
Mother smokes Risk of hospitalization vs.
outpatient treatment
Not included in multivariate
analysis NS in bivariate analysis
(P= 0.21)
Somech 2006
Canada [34]
Prospective study of 195 infants
(mean age 3.8 months) with
laboratory-confirmed
RSV infection
Exposure to smoke
from at least one
family member
Hospitalization (113) vs.
outpatient treatment (82)
of RSV
ETS exposure was unrelated
to hospitalization
(P value not reported)
No multivariate analysis
performed (confounding
bias)
Disease severity in children in the general population hospitalized with RSV illness
Al-Sonboli 2006
Yemen [35]
Prospective study of 325
children aged ≤2 with
acute respiratory illness
seeking emergency or
outpatient services at a
hospital (82% RSV)
Smoking in
household
Severe hypoxia among
RSV-positive group
aOR, 3.8 (95% CI, 1.5–9.8);
P=0.002
No description of how
smoke exposure or other
family characteristics were
ascertained (exposure bias)
Bradley 2005
US [36]
Prospective evaluation of
206 infants hospitalized
with their first episode of
severe RSV bronchiolitis
Current maternal
smokingMaternal
smoking status
during pregnancy
Lowest oxygen
saturation rate
Current maternal smoking was
associated with lower oxygen saturation,
P =0.05No effect of smoking during
pregnancy only (n = 10)
No significant bias
concerns affecting the
relationship of ETS and
outcome
Chatzimichael 2007
Greece [37]
Prospective study of
240 children aged
6–24 months hospitalized
for bronchiolitis
Exposure to >5
cigarettes per day in
the home; children
with prenatal exposure
were excluded
Disease severity measured
with a clinical rating tool
that included hypoxemia
aOR, 2.2 (95% CI, 1.1–3.6); P= 0.003 Unclear RSV disease
classification; severity tool
used
Sritippayawan 2006
Thailand [38]
Study of 19 children
(median age 9 months)
Exposure measured
by urinary cotinine
Hypoxemia (oxygen
saturation <92%)
High risk of selective
reporting biasRisk of
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Table 3 Studies examining disease severity (N= 8) (Continued)
admitted to the hospital
with laboratory-confirmed RSV LRTI
Cotinine was detected in 100% of
infants with hypoxia vs. 33% of those
without hypoxia; P= 0.01
confounding not clear;
regression analysis appears
to have been performed but
was insufficiently reported
so it was not possible to tell
which factors were
controlled for
aOR = adjusted (multivariate) odds ratio; BPD=bronchopulmonary dysplasia; CI = confidence interval; ETS = environmental tobacco smoke; LRTI = lower respiratory tract infection; NS = not significant; RSV = respiratory
syncytial virus.
D
iFranza
et
al.BM
C
Pediatrics
2012,12:81
Page
11
of
16
http://w
w
w
.biom
edcentral.com
/1471-2431/12/81
conflicting associations with three different outcomes:
RSV LRTI, all-cause hospital admission, and length of
hospital stay [19]. Measures of smoke exposure in the
home and maternal smoking gave conflicting results
when evaluated in 2 studies [6,20], including a study in
premature infants [20]. Finally, a small case–control
study in a general population in Turkey found that sev-
eral exposure variables (only mother smoking, both par-
ents smoking, any parent smoking, and serum cotinine)
were associated with significant increase in risk of ad-
mittance to the ED; however, only father smoking was
significantly associated with a decrease in risk [23].
Of the studies of laboratory-confirmed RSV
hospitalization described in Table 1, 5 were conducted
in premature infants and 9 were conducted in general
populations. All 5 studies of laboratory-confirmed RSV
in premature infants found increased risk related to ETS
exposure in either bivariate or multivariate analyses
[9,10,19-21] (Table 1). The 2004 case–control study of
infants with a gestational age of 33 to 35 weeks by
Figueras-Aloy et al. [21] found an OR of 1.62 in the bi-
variate analysis that did not remain significant in the
multivariate analysis. However, the same researchers
published a much larger cohort study in 2008, in a pre-
mature population with a gestational age of 32 to
35 weeks, reporting a nearly identical aOR (1.61) for ma-
ternal smoking that remained significant in the multi-
variate analysis [20]. The authors of the 2004 study note
that the prevalence of ETS exposure decreased in Spain
during the years before the study (52% during the 1999–
2000 RSV season compared with 30% in this study) be-
cause of anti-smoking campaigns or health education
[21]. The significant association in the larger study sug-
gests that the earlier study was underpowered for the
multivariate analysis.
Of the 9 studies of laboratory-confirmed RSV illness
in general populations described in Tables 1, 2 were pro-
spective cohort studies and 7 were case–control studies
(Table 1). Risk of RSV LRTI in an outpatient office set-
ting [22] and risk of RSV hospitalization from ETS ex-
posure (smoking in the household, but not from
maternal smoking during pregnancy) [6] were not sig-
nificant in the cohort studies.
The 7 case–control studies of laboratory confirmed
RSV illness in general populations ranged in size from
20 to 2,564 cases (Table 1), and all found a significant
association between ETS exposure and risk of RSV
hospitalization in either the multivariate or bivariate
analyses, with the ORs from the 4 largest studies cluster-
ing tightly between 1.35 and 1.6. The 3 smallest case–
control studies included in Table 1 did not provide ORs
but compared ETS exposure prevalence between the
cases and healthy controls [23-25]. All 3 found signifi-
cant differences in ETS exposure in cases versus
controls. The Turkish study also demonstrated signifi-
cantly higher cotinine levels in serum samples from
cases than from healthy controls [23]. In a case–control
study of Alaska native children, risk was apparent in the
bivariate analysis, but not in the multivariate analyses
[12] (Table 1). The authors noted that misclassification
of exposure status may have been a problem. The study
was conducted in Alaska, where children spend much
time indoors during the winter RSV season and could be
exposed to ETS when visiting other houses or commu-
nity buildings. This appears likely, because there were
smokers living in the households of 59% of the controls
and 68% of the cases. The consistency of findings associ-
ating ETS exposure and increased risk of serious RSV,
coupled with the inconsistency of the variables asso-
ciated with these significant results, highlights the chal-
lenges of assessing and categorizing ETS exposure.
ETS exposure and clinically diagnosed RSV disease
As with the studies in Table 1, the studies in Table 2
seek to answer the question, does ETS exposure increase
the risk that an uninfected child will develop serious
RSV? In these studies, however, the RSV diagnosis was
based on clinical findings rather than a laboratory test.
Table 2 presents 8 studies, 6 of which reported a signifi-
cant association between ETS exposure and bronchiolitis
hospitalization or outpatient treatment. Because other
organisms may cause bronchiolitis, there may be pos-
sible misclassification of RSV disease status [33].
The large general population cohort studies including
bronchiolitis hospitalization as an outcome by Boyce
et al. [4], Carroll et al. [28], and Koehoorn et al. [29] are
in agreement with the 12 studies in Table 1 that identi-
fied an increased risk of RSV hospitalization associated
with ETS exposure. Carroll and colleagues also demon-
strated increased risk of ED visit or clinic visit for bron-
chiolitis and bronchiolitis diagnosis related to ETS
exposure [28].
In other studies assessing risk of bronchiolitis LRTI in
children presenting in the office setting, 2 studies found
an increased risk for at least one ETS variable [28,31],
whereas 2 other studies did not [29,30]. Of these, the
positive study by Carroll et al. [28] had the greatest stat-
istical power.
Only the Holman study assessed risk of death from
bronchiolitis; the risk was increased by maternal smok-
ing (aOR, 1.6) [3].
ETS exposure and severity of RSV illness
The 8 studies in Table 3 address the question, given that
a child has contracted RSV, does ETS exposure increase
the severity of illness? Four studies compared ETS ex-
posure in children hospitalized for RSV and children
with RSV who were not hospitalized. Three of these
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studies, including a small study of premature infants
with BPD, found no effect of ETS exposure on the likeli-
hood of hospitalization for RSV [2,32,34]. One small
study found an effect of ETS exposure, but only 40% of
the hospitalized children were found to have RSV infec-
tions, with the remaining 60% representing bronchiolitis
caused by other viruses [33].
Four studies examined clinical severity (degree of hyp-
oxemia) of RSV LRTIs among children hospitalized for
treatment. All 4 found that ETS exposure was associated
with more severe illness (Table 3). Bradley et al. found
that hypoxemia was associated with postnatal but not
prenatal smoke exposure [36]. Chatzimichael et al. found
that breastfeeding was protective against the effect of
ETS exposure on disease severity [37]. Based on a small
number of studies of RSV severity, ETS exposure does
not appear to increase the risk of hospitalization versus
outpatient treatment among children infected with RSV,
but hospitalized RSV patients exposed to ETS have more
severe disease.
Summary of potential bias in observational studies of ETS
exposure and serious RSV disease
As the studies reviewed were observational, we evaluated
the primary sources of bias that could potentially affect
the estimates of association with ETS exposure (Add-
itional file 2). We found that 21 of the 30 studies con-
firmed the RSV diagnosis through laboratory testing for
RSV or multiple respiratory illnesses including RSV in
all of the study populations [2,5,6,9-12,19-26,32-36,38].
The remaining studies had a risk of disease misclassifica-
tion bias of RSV because diagnostic codes (primarily for
bronchiolitis) or diagnoses from medical records were
used [3,4,27-31,37,39]. Misclassification of RSV disease
may attenuate the association of ETS exposure and se-
vere RSV disease, and the studies of clinically diagnosed
RSV patients may provide conservative estimates of ETS
exposure risk.
Overall, we identified few studies that had potential se-
lective reporting bias, confounding bias, exposure ascer-
tainment bias for ETS, or participant selection bias.
Selective outcome reporting was a potential problem in 2
studies [38,39], meaning that outcomes were not described
sufficiently to determine which factors were included and
potentially controlled for in the analysis. Although con-
founding is a threat across observational studies (because
it is difficult to control for both measureable and unmeas-
urable factors), multivariate analyses were not conducted
in a number of studies [23-25,32,34,38], which could
lead to an overestimate of the effect of ETS exposure.
One study had a high risk of participant selection bias,
where both cases and controls were diagnosed with
bronchiolitis [33]. Only 2 studies had an unclear risk
of ETS exposure [12,35]. Al-Sonboli and colleagues
[35] did not describe how the ETS exposure data or
other demographic data were obtained. In the Bulkow
et al study, ETS exposure was highly prevalent in the
community (in both cases and controls) and indoor
visiting was frequent during the winter RSV season
[12]; therefore, the ETS exposure variable “smoker in
household” was not an adequate proxy for exposure in
this population.
No statistical analysis of the risk of bias across studies
was performed for this review.
Discussion
The impact of ETS exposure on RSV disease in infants
and young children is consistent among studies using
laboratory confirmation of RSV infection and clinical
diagnosis of bronchiolitis or RSV. Among 14 population-
based studies that examined the risk of admission to
the hospital or ED for RSV disease, 12 showed that at
least one type of ETS exposure in each study was asso-
ciated with a significant adverse outcome in the bivari-
ate or multivariate analysis. The observation that ETS
exposure increases the risk that a child will develop
RSV disease that will require hospitalization is robust
because these studies used different methods (prospect-
ive, retrospective, cohort, case–control) in different
patient populations (infants who were premature, term,
or with compromising conditions), in a variety of coun-
tries and cultures. In addition, the evidence suggests
that ETS exposure is associated with more severe hyp-
oxia among children hospitalized for RSV [35-38], and
one study found an increased risk of mortality from
bronchiolitis [3].
Among studies in premature infants, 5 [9,10,19-21] of
7 [9,10,19-21,27,32] found ETS exposure to be a signifi-
cant risk factor in bivariate or multivariate analysis, in-
cluding 5 of the 6 [9,10,19-21,32] studies assessing
laboratory-confirmed RSV. One study contradicting this
conclusion did not have laboratory confirmation of the
diagnosis and relied on a claims database, rather than
direct data collection, for ascertainment of the ETS ex-
posure status [27]. Misclassification of disease status or
missed diagnosis may have contributed to the negative
findings in this study. The other was a small study of 30
premature infants with BPD on home oxygen therapy,
16 of whom developed RSV [32].
The evidence concerning whether ETS exposure
increases the risk of mild RSV infection is much less
convincing. In a very large study, Carroll et al. found
ETS exposure to be associated with only a small
increased risk of RSV illness (OR, 1.06) presenting in the
outpatient setting [28]. If this OR represents the true
risk, the Holberg [22] and Marbury [30] studies, which
did not find a risk, would have been underpowered to
detect it because of smaller sample sizes. Because nearly
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all children contract RSV during the first few years of
life [1] and most cases are mild [2], there may be a ceil-
ing effect. If children with no ETS exposure are almost
certain to contract RSV, ETS exposure can increase the
risk of mild infection only slightly.
Misclassification of ETS exposure is a major challenge
in studying associations of ETS exposure with disease.
Misclassification of exposure status produces a bias in
the direction of reducing the apparent magnitude of the
risk, leading to either an underestimate of the true ETS
exposure risk or to a null finding. Misclassification of an
infant or child’s ETS exposure comes from researchers’
use of one or a few measures of possible exposure,
which actually can come through many avenues. Exam-
ples include in utero exposure through active and pas-
sive maternal smoking and postnatal smoking by the
mother, father, other individuals living in the home, visi-
tors, and babysitters. ETS exposure outside the home
occurs in public places, day care settings, and houses of
friends and relatives. No study in this review gathered
exposure data for all potential sources. The smoking sta-
tus of, for example, the parent is a poor proxy for this
global exposure as demonstrated by cotinine level stud-
ies. Urinary or serum cotinine (a metabolite of nicotine)
is an objective measure of ETS exposure but provides in-
formation regarding only the previous 48 to 72 hours of
exposure [40]. In one study, infants whose parents
reported that they did not smoke had mean cotinine
levels that were 80% as high as those for infants with
one smoking parent [39]. Some infants of nonsmoking
parents had higher cotinine levels than some infants
with two smoking parents [39].
Confounding bias is another potential obstacle to de-
termining the association between ETS exposure and
serious RSV disease. A few studies found an ETS expos-
ure effect in bivariate analyses but not in multivariate
analyses after adjustment for other factors [11,21,39].
Multivariate models that include ETS exposure and its
related factors may be difficult to interpret due to poten-
tial collinearity. Smoking status has a well-known associ-
ation with socioeconomic status (SES) [41], and SES is
predictive of ETS exposure in children [42]. Therefore,
SES may be a proxy for global ETS exposure over the
early years of life. In addition to SES, smoking status is
also predicted by race, educational attainment, and mari-
tal status [43]. Few of the multivariate studies provided a
rationale for their selection of control variables. In
reporting of future studies, greater details about the
multivariate modeling steps may aid in assessment of
collinearity when significant bivariate outcomes become
nonsignificant in multivariate analysis.
This review has several limitations. The search was
limited to studies published from 1990 to April 2009 in
the English language. We searched only Pubmed and
Embase and did not attempt to locate unpublished stud-
ies. The nature of the primary studies precluded a meta-
analysis. The large retrospective database analyses
included in this study (Table 2) all depended on bron-
chiolitis or RSV disease classification from diagnostic
codes or medical record diagnosis. Although RSV is a
leading cause of LRTI in infants and children, identifying
the etiology of LRTI is not systematically undertaken in
EDs or physician offices. Methods and reporting of ETS
exposure ascertainment in these studies also varies
widely. However, in most studies, data on the child’s
ETS exposure level ultimately are gathered from parent
or caregiver report, whether through direct data collec-
tion for the study or, for example, through retrospective
review of the mother’s prenatal health records. Our re-
view highlights the inherent difficulty of accurately
assessing global ETS exposure.
Conclusion
Overall we found ample evidence that ETS exposure
places infants and young children at increased risk of
hospitalization for RSV-attributable LRTIs, and increases
the severity of illness as measured by degree of hypoxia
among children hospitalized for RSV. Based on a small
number of studies, we also found evidence that ETS ex-
posure does not increase the likelihood among general
populations with RSV of hospitalization versus out-
patient treatment.
The prevention of serious RSV illness provides one
more rationale for protecting infants and young children
from exposure to tobacco smoke, especially high-risk
groups such as premature infants and those with chronic
conditions who are considered at increased risk of ser-
ious RSV disease.
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